People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

President Donald Trump announced nine of the largest drugmakers in the U.S. and Europe agreed to voluntarily sell their ...

Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi have agreed to drug pricing deals.

Novo Nordisk A/S (NYSE:NVO) is one of the Best Non-US Stocks to Buy According to Hedge Funds. On December 12, Novo Nordisk A/S (NYSE:NVO) announced receiving a positive opinion by the European ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...

In his latest effort to lower drug costs, President Donald Trump unveiled Friday “Most Favored Nation” pricing deals with nine more pharmaceutical companies.

Makers of Ozempic and other weight loss drugs are facing lawsuits that allege the drugs cause blindness in some patients.

A handful of drugmakers have already disclosed pricing deals with the Trump administration and plan to sell certain drugs at a discount on TrumpRx, the White House's new direct-to-consumer website ...

GLP-1s improved outcomes in patients with heart failure with preserved ejection fraction, with or without obesity, but those ...

The pharmaceutical sector's most intense rivalry is escalating. Eli Lilly has unveiled pivotal Phase 3 trial results for its ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...